Clinical trial
Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone…
NCT00002787 · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Other · Completed
Key facts
| NCT number | NCT00002787 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation |
| Official title | Phase I Trial of Post Transplant Immunization With Autologous Myeloma Idiotype-KLH/GM-CSF In Myeloma Patients Following Autologous or Allogeneic Marrow or Stem Cell Transplantation |
| Lead sponsor | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma |
| Intervention type | Biological, Other |
| Interventions | autologous immunoglobulin idiotype-KLH conjugate vaccine, sargramostim, aldesleukin, laboratory biomarker analysis |
| Enrollment | 22 |
| Start date | Mar 1, 1996 |
| Primary completion | Dec 1, 2002 |
| First posted | May 21, 2004 |
| Last update posted | May 6, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: